Precision pathways: optimising amyloid PET for sustainable Alzheimer’s disease care
Journal of Neurology · 2026-06 · 273 (6)
DOI: 10.1007/s00415-026-13874-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Neurology, online erschienen am 26.05.2026. Verfasst von Silvia Daniela Morbelli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Alzheimer Disease, Positron-Emission Tomography, Amyloid beta-Peptides, Precision Medicine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
The approval of anti-amyloid therapies has reshaped Alzheimer’s disease from a clinically defined syndrome to a biologically confirmed and treatment-oriented condition. This transition places biomarkers, particularly amyloid positron emission tomography (Aβ-PET), at the centre of diagnostic precision, patient selection, safety governance, and therapeutic monitoring. Aβ-PET provides high specificity for confirming cerebral amyloid pathology, especially in cases with discordant or inconclusive fluid biomarkers, and supports staging through semi-quantitative assessment using standardised Centiloid metrics. In patients considered for anti-amyloid therapies, baseline Aβ-PET refines eligibility and risk–benefit profiling when integrated with MRI and APOE genotyping. During treatment, longitudinal Aβ-PET enables objective assessment of pharmacodynamic target engagement and treatment-related amyloid clearance, supporting response-adapted strategies and, in selected cases, therapy discontinuation. Beyond its clinical role, Aβ-PET has strategic organisational and economic implications. Its value is maximised when embedded within structured, stepwise diagnostic pathways that use scalable fluid biomarkers for triage and reserve Aβ-PET for high-impact decisions. However, implementation is challenged by regional heterogeneity, capacity constraints, and limited harmonisation across centres. Coordinated hub-and-spoke models, quantitative standardisation, and prospective registry-based data collection are essential to ensure the equitable and sustainable integration of anti-amyloid therapies into clinical practice. Aβ-PET has evolved from a confirmatory diagnostic tool to a strategic instrument that enables biologically driven, outcome-oriented care for patients with Alzheimer’s disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, University of Turin, Turin, Italy.
- Nuclear Medicine Unit, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.
- "Rita Levi-Montalcini" Department of Neuroscience, University of Torino, Turin, Italy.
- Neurology Unit 2U, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.
- Department of Neuroscience, University of Padova, Padua, Italy.
- Padova Neuroscience Center (PNC), University of Padova, Padua, Italy.
Zitieren
APA
Morbelli, S. D., Bozzali, M., Cagnin, A., Cecchin, D., Chiti, A., & Filippi, M. (2026). Precision pathways: optimising amyloid PET for sustainable Alzheimer’s disease care. Journal of Neurology, 273(6). https://doi.org/10.1007/s00415-026-13874-2
Vancouver
Morbelli SD, Bozzali M, Cagnin A, Cecchin D, Chiti A, Filippi M. Precision pathways: optimising amyloid PET for sustainable Alzheimer’s disease care. Journal of Neurology. 2026;273(6). doi:10.1007/s00415-026-13874-2
BibTeX
@article{Morbelli2026,
author = {Morbelli, Silvia Daniela and Bozzali, Marco and Cagnin, Annachiara and Cecchin, Diego and Chiti, Arturo and Filippi, Massimo},
title = {Precision pathways: optimising amyloid PET for sustainable Alzheimer’s disease care},
journal = {Journal of Neurology},
year = {2026},
volume = {273},
number = {6},
doi = {10.1007/s00415-026-13874-2}
}
EUVIMED